Exclusively available in the UK and Ireland through Grafton Optical, E-Eye uses patented IRPL® (Intense Regulated Pulsed Light) technology specifically designed for the treatment of Dry Eye due to Meibomian Gland Dysfunction (MGD).
As well as being available for purchase, Grafton Optical are now introducing an E-Eye rental scheme throughout the UK and Ireland. For further information and pricing please contact Grafton Optical on email@example.com.
E-Eye uses a unique patented Intense Regulated Pulsed Light (IRPL®) technology to help regenerate the function of the Meibomian glands and improve the quality of their secretions.
This new type of polychromatic pulsed light produces perfected calibrated and homogenously sequenced light pulses which stimulate the parasympathetic nerves. This in turn encourages the Meibomian glands to restore their natural lipid flow, reducing tear evaporation and preventing the eyes from becoming dry.
In most cases, Dry Eye symptoms will significantly improve after 3 sessions, carried out over 45 days (Day 0/ Day 15/ Day 45). For 60% of patients results can last up to 3 years.
• Painless, non-invasive and affordable
• Fast results – sessions are completed in a matter of minutes
• Clinical studies with a 90% satisfaction rate on the first 2 sessions
• 95.7% of patients recommend the treatment
• 55% of patients don’t use eye drops anymore
• 82.6% of patients have symptom improvements
Brian Bowles, Managing Director of Grafton Optical says “We have seen huge interest and success with the E-Eye since its launch in the UK last year. It offers huge benefits not only to patients suffering from MGD related Dry Eye but also to practices wishing to increase their income.”
E-Eye is 100% developed and made in France by ESW Vision, the world’s largest IPL device manufacturer.
For a quote or to arrange a demo of the E-Eye please contact firstname.lastname@example.org or call us on +44 (0)1923 233980.
Grafton Optical is one of the UK’s leading suppliers of ophthalmic instruments, equipping and servicing independent and larger chain opticians as well as Britain’s hospitals.